Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)

被引：0

作者：

Kapoun, A. ^{[1
]}

O'Reilly, E. ^{[2
]}

Cohn, A. ^{[3
]}

Bendell, J. C. ^{[4
]}

Smith, L. ^{[5
]}

Strickler, J. H. ^{[6
]}

Gluck, W. ^{[7
]}

Liu, Y. W. ^{[1
]}

Wallace, B. ^{[1
]}

Tam, R. ^{[1
]}

Cancilla, B. ^{[1
]}

Brunner, A. ^{[1
]}

Hill, D. ^{[1
]}

Zhou, L. ^{[1
]}

Dupont, J. ^{[1
]}

Zhang, C. ^{[1
]}

Wang, M. ^{[1
]}

机构：

[1] OncoMed Pharmaceut, Davis, CA USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Rocky Mt Canc Ctr, Denver, CO USA

[4] Sarah Canon Res Inst, Nashville, TN USA

[5] START, San Antonio, TX USA

[6] Duke Univ, Durham, NC USA

[7] Greenville Hosp Syst, Greenville, SC USA

来源：

EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷

关键词：

D O I：

10.1016/S0959-8049(14)70591-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

465

引用

页码：152 / 152

页数：1

共 50 条

[41] A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
Bekaii-Saab, Tanios S.
Starodub, Alexander
El-Rayes, Bassel F.
O'Neil, Bert H.
Shanda, Safi
Ciombor, Kristen Keon
Noonan, Anne M.
Hanna, Wahid Tewfik
Sehdev, Amikar
Shaib, Walid Labib
Mikhail, Sameh
Neki, Anterpreet S.
Oh, Cindy
Li, Youzhi
Li, Wei
Borodyansky, Laura
Li, Chiang
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42] Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).
Goldstein, David
EI-Maraghi, Robert Hassan
Hammel, Pascal
Heinemann, Volker
Kunzmann, Volker
Sastre, Javier
Scheithauer, Werner
Siena, Salvatore
Macarulla, Teresa
Teixeira, Luis
Tortora, Giampaolo
Van Laethem, Jean Luc
Penenberg, Darryl Neil
Lu, Brian
Romano, Alfredo
Von Hoff, Daniel D.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[43] Total healthcare, treatment, and supportive care costs among metastatic pancreatic cancer (MPC) patients (pts) treated with either nab-paclitaxel/gemcitabine (nab-P plus G) or FOLFIRINOX (FFX) in the first-line (1L) setting.
Ung, Brian
Patel, Manish
Pelletier, Corey
Ni, Quanhong
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
[44] HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies
O'Reilly, Eileen Mary
Borazanci, Erkut Hasan
Yu, Kenneth H.
Varghese, Anna M.
Estrella, Hayley
Kamins, David
Melink, Teresa
Dorr, Kirsten
Maffuid, Paul
Gutheil, John
Wang, Judy Sing-Zan
Bauer, Todd Michael
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).
Chiorean, E. Gabriela
Von Hoff, Daniel D.
Ervin, Thomas J.
Arena, Francis P.
Infante, Jeffrey R.
Bathini, Venu Gopal
Wood, Tina Evans
Mainwaring, Paul N.
Muldoon, Robert T.
Clingan, Philip R.
Kunzmann, Volker
Ramanathan, Ramesh K.
Tabernero, Josep
Goldstein, David
Ko, Amy
Lu, Brian
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[46] Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study
Vincent, Picozzi
Caio, Rocha Lima
Vaibhav, Sahai
Diane, Simeone
Allyson, Ocean
Philip, Philip
Wasif, Saif
Aparna, Kalyan
Michael, Ondovik
Jack, Shiansong Li
Victoria, Manax
ANNALS OF ONCOLOGY, 2016, 27 : 83 - 84
[47] A phase 1b, open-label, safety, pharmacokinetic, and pharmacodynamic study of an anti-super-enhancer triptolide analogue with nab-paclitaxel plus gemcitabine in patients with metastatic adenocarcinoma of the pancreas.
Park, Joon Oh
Hong, Jung Yong
Kim, Seung Tae
Park, Young Suk
Saluja, Ashok
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS769 - TPS769
[48] A phase 1b/2 study of CD40 agonistic monoclonal antibody (APX005M) together with gemcitabine and nab-paclitaxel with or without nivolumab in untreated metastatic pancreatic adenocarcinoma patients
O'Hara, Mark
Mick, Rosemarie
Lyman, Jaclyn
Xu, Jingying
Hosseini, Maryam
LaVallee, Theresa
Gherardini, Pier Federico
Vance, Barbara
Trifan, Ovid
Dugan, Ute
Shalabi, Aiman
Ibrahim, Ramy
Vonderheide, Robert
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[49] Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis
Oberstein, Paul E.
Rahma, Osama
Beri, Nina
Stoll-D'Astice, Amy
Kawaler, Emily A.
Dolgalev, Igor
Werba, Gregor
Cardo-Ruffino, Victoire
Bollenrucher, Naima
Costa, Andressa Dias
Nazeer, Saloney
Squires, Matthew
Nowak, Jonathan
Bar-Sagi, Dafna
Wolpin, Brian
Simeone, Diane M.
Dougan, Stephanie K.
CANCER RESEARCH, 2022, 82 (22)
[50] Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)
Evans, T.
Ramanathan, R. K.
Yazji, S.
Glynne-Jones, R.
Anthoney, A.
Berlin, J.
Valle, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →